Fc variants
Disclosed are Fc-containing proteins comprising a binding region and a variant Fc region that can elicit one or more immune effector function and/or bind to an Fc receptor more effectively than a similar Fc-containing protein comprising a wild type Fc region. Also disclosed are nucleic acids encoding such Fc-containing proteins, methods for making such proteins, and methods of treatment utilizing such proteins.
1. An IgG1 Fc-containing protein comprising a heterodimeric human IgG1 Fc region and a binding region, wherein the IgG1 Fc region comprises an A chain and a B chain,
wherein the A chain and B chain comprise the following amino acid substitutions relative to a wild type human IgG1 Fc polypeptide chain, numbered according to the EU system:
(a) the A chain comprises Q311M and K334V substitutions and the B chain comprises L234Y, E294L, and Y296W substitutions or vice versa;
(b) the A chain comprises L235S, S239D, and K334V substitutions and the B chain comprises L234Y, K290Y, and Y296W substitutions or vice versa;
(c) the A chain comprises Q311M and K334V substitutions and the B chain comprises L234Y, F243V, and Y296W substitutions or vice versa;
(d) the A chain comprises S239D and K334V substitutions and the B chain comprises L234Y, Y296W, and S298C substitutions or vice versa;
(e) the A chain comprises E294L and K334V substitutions and the B chain comprises L234Y, K290Y, and Y296W substitutions or vice versa; and
(f) the A chain comprises E294L and K334V substitutions and the B chain comprises L234Y, Y296W, and S298C substitutions or vice versa;
wherein the IgG1 Fc-containing protein binds to human FcγRIIIA-158F and/or FcγRIIIA-158V with a K D of less than or equal to one fifth of the K D with which a second protein binds to human FcγRIIIA-158F and/or FcγRIIIA-158V, wherein the second protein is the same as the IgG1 Fc-containing protein except that it contains a wild type human IgG1 IgG Fc region without substitutions.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an IgG1 Fc-containing protein comprising a heterodimeric human IgG1 Fc region and a binding region,
wherein the IgG1 Fc region comprises an A chain and a B chain, and
wherein the A chain and B chain comprise the following amino acid substitutions relative to a wild type human IgG1 Fc polypeptide chain, numbered according to the EU system:
(a) the A chain comprises Q311M and K334V substitutions and the B chain comprises L234Y, E294L, and Y296W substitutions or vice versa;
(b) the A chain comprises L235S, S239D, and K334V substitutions and the B chain comprises L234Y, K290Y, and Y296W substitutions or vice versa;
(c) the A chain comprises Q311M and K334V substitutions and the B chain comprises L234Y, F243V, and Y296W substitutions or vice versa;
(d) the A chain comprises S239D and K334V substitutions and the B chain comprises L234Y, Y296W, and S298C substitutions or vice versa;
(e) the A chain comprises E294L and K334V substitutions and the B chain comprises L234Y, K290Y, and Y296W substitutions or vice versa; and
(f) the A chain comprises E294L and K334V substitutions and the B chain comprises L234Y, Y296W, and S298C substitutions or vice versa;
wherein the IgG1 Fc-containing protein binds to human FcγRIIIA-158F and/or FcγRIIIA-158V with a K D of less than or equal to one fifth of the K D with which a second protein binds to human FcγRIIIA-158F and/or FcγRIIIA-158V, wherein the second protein is the same as the IgG1 Fc-containing protein except that it contains a wild type human IgG1 IgG Fc region without substitutions.
3. The IgG1 Fc-containing protein of claim 1 , wherein the IgG1 Fc-containing protein binds to human FcγRIIIA-158F and/or FcγRIIIA-158V with a K D of less than or equal to one tenth of the K D with which the second protein binds to human FcγRIIIA-158F and/or FcγRIIIA-158V.
4. The IgG1 Fc-containing protein according to claim 1 or 3 , wherein the A chain comprises the amino acid sequence of SEQ ID NO: 8; and the B chain comprises the amino acid sequence of SEQ ID NO: 10 or 18; or vice versa.
5. The IgG1 Fc-containing protein according to claim 1 or 3 , wherein said IgG1 Fc-containing protein comprises the pair of amino acid sequences selected from the group consisting of: SEQ ID NO: 8 and SEQ ID NO:10; SEQ ID NO: 16 and SEQ ID NO:18; SEQ ID NO: 12 and SEQ ID NO:10; SEQ ID NO: 14 and SEQ ID NO:10; SEQ ID NO: 20 and SEQ ID NO:18; SEQ ID NO: 22 and SEQ ID NO:18; SEQ ID NO: 2 1 1 and SEQ ID NO:10; SEQ ID NO: 26 and SEQ ID NO:10; SEQ ID NO: 28 and SEQ ID NO:18; SEQ ID NO: 30 and SEQ ID NO:18; SEQ ID NO: 32 and SEQ ID NO:18; SEQ ID NO: 34 and SEQ ID NO:18; SEQ NO:37 and SEQ ID NO:39; and SEQ NO:37 and SEQ ID NO: 1 11.
6. The IgG1 Fc-containing protein according to claim 1 or 3 , wherein the IgG1 Fc-containing protein is defucosylated.
7. The IgG1 Fc-containing protein according to claim 1 or 3 , wherein the IgG1 Fc-containing protein is made in a CHO cell.
8. The IgG1 Fc-containing protein according to claim 1 or 3 , wherein the IgG1 Fc-containing protein is an antibody.
9. The IgG1 Fc-containing protein of according to claim 1 or 3 , wherein the IgG1 Fc-containing protein is an IgG1 Fc fusion protein.
10. The Fc-containing protein according to claim 1 or 3 , wherein the IgG1 Fc-containing protein is a bispecific antibody and/or is a full length human IgG1 antibody.